Collegium Pharmaceutical: Pain Cash Flows Are Funding An ADHD Re-Rating (NASDAQ:COLL)
· seekingalpha.com
Collegium Pharma (COLL) pivots to a CNS/ADHD growth platform via AZSTARYS, targeting 2026 revenue/EBITDA upside; shares look undervalued—read now.
I have a strong inclination towards high-growth companies, often treading in sectors poised for exponential expansion. My expertise lies in understanding and in...